Lercanidipine

Drug Profile

Lercanidipine

Alternative Names: Cardiovasc; Carmen; Corifeo; Lercadip; Lercapdip; Lerdip; Lerez; Lerka; Lerzam; R 75; REC 152375; TJN 324; Vasodip; Zanedip; Zanidip

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Recordati
  • Developer A.R. Kamm Associates; Algorithm; Andromaco; Dexcel-Pharma; Digital Gene Technologies; Elmor; Fako Ilaclari; Forest Laboratories; Fournier Pharma Inc; Gador; Grunenthal; Himont Pharmaceutical; Laboratoires Fournier; Laboratorios Sanfer; LG Life Sciences; Meda; Orient Europharma; Recordati; Robapharm; Solvay; UCB; Zuoz Pharma
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top